Baidu
map
INT J ONCOL 润色咨询

INTERNATIONAL JOURNAL OF ONCOLOGY

出版年份：1992 年文章数：3862 投稿命中率： 开通期刊会员，数据随心看

出版周期：Monthly 自引率：3.1% 审稿周期： 开通期刊会员，数据随心看

前往期刊查询
期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索

期刊讨论

  1. [GetPortalCommentsPageByObjectIdResponse(id=2173925, encodeId=eff121e392549, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向：肿瘤<br>经验分享：2023.12.09投稿，开贴求经验, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8eb16517785, createdName=ms1000000657368188, createdTime=Sat Dec 09 21:09:03 CST 2023, time=2023-12-09, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2187816, encodeId=a73f218e81621, content=审稿速度:6.0 | 投稿命中率:50.0<br>经验分享：9.28 投稿<br>9.30 修改格式 正式 under review<br>12.27 返回外审意见、<br>1.26 返修<br>1.27 编辑提出问题回答<br>2.15 再次返修<br>2.16接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=883e8850373, createdName=ms9000000079865054, createdTime=Sat Feb 17 21:01:29 CST 2024, time=2024-02-17, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2129832, encodeId=1a562129832f2, content=偏重的研究方向：肿瘤<br>经验分享：开帖求投稿经验 2023-2-14投稿综述 2023-2-17修改格式后，正式投稿并under review 2023-4-7发邮件问结果，立马有邮件返回说正在外审，还没有结果 2023-4-20再次发邮件问结果，立马有邮件返回说正在外审，仍旧没有结果 2023-5-3仍旧显示under review, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=126, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1917110347, createdName=ruiruima, createdTime=Wed May 03 12:28:26 CST 2023, time=2023-05-03, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1192333, encodeId=82e7119233345, content=审稿速度:1.0 | 投稿命中率:95.0<br>经验分享：12月10投，13外审，28出外审结果，2月5日修回，10接受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=172, replyNumber=18, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c4f5685200, createdName=ms9000001565211375, createdTime=Fri Feb 11 14:48:33 CST 2022, time=2022-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=580056, encodeId=46865800565a, content=文章接收了，下次不会再有这个杂志了，已被我们课题组拉入黑名单。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=161, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/c887015508b0c6ba53504e915b77a54c/59b1727e79c41e7236679601545c8119.jpg, createdBy=da932211214, createdName=牛肉盖饭菌, createdTime=Mon Nov 18 00:00:00 CST 2019, time=2019-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2171541, encodeId=96d121e15410e, content=求经验，想问问各位大佬，Under review编辑内审一般持续多长时间，进入peer review杂志社会发邮件吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=89, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16275416139, createdName=ms9000000361361306, createdTime=Tue Nov 28 20:44:38 CST 2023, time=2023-11-28, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2117052, encodeId=9b20211e052a1, content=偏重的研究方向：肿瘤;miRNA;卵巢癌<br>经验分享：2.14投稿<br>2.21改格式，Under review直到现在, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=117, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ffcd5307805, createdName=1487e742m42(暂无昵称), createdTime=Wed Mar 01 14:52:29 CST 2023, time=2023-03-01, status=1, ipAttribution=内蒙古), GetPortalCommentsPageByObjectIdResponse(id=2167435, encodeId=7e2f216e43593, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：癌症<br>经验分享：耗时五个月，五次返修，接受，编辑很好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230724/f6ff49274b4c450bb5ce22714896fd31/ef43ceb74c4f403797e71c4c086060e6.jpg, createdBy=33518647109, createdName=病理, createdTime=Wed Nov 08 17:28:30 CST 2023, time=2023-11-08, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2147312, encodeId=7b51214e31242, content=审稿速度:6.0 | 投稿命中率:95.0<br>偏重的研究方向：肿瘤;miRNA<br>经验分享：他的under review就是送外审，很久，我的从2月到6月等了四个月，然后6月返修7月就接收了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=114, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e85e8128411, createdName=ms1000000775790410, createdTime=Mon Jul 10 17:00:54 CST 2023, time=2023-07-10, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2114730, encodeId=9c2f2114e3000, content=开个贴分享投稿进度，求锦鲤...<br>2-5投稿，2-9要求改figure清晰度，当天返修，至今还是submitted, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=102, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8be8102949, createdName=ms7000002043514455, createdTime=Wed Feb 15 13:49:28 CST 2023, time=2023-02-15, status=1, ipAttribution=北京)]
    2023-12-09 ms1000000657368188 来自四川省

    审稿速度:2.0 | 投稿命中率:50.0
    偏重的研究方向：肿瘤
    经验分享：2023.12.09投稿，开贴求经验

    6

    展开6条回复
  2. [GetPortalCommentsPageByObjectIdResponse(id=2173925, encodeId=eff121e392549, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向：肿瘤<br>经验分享：2023.12.09投稿，开贴求经验, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8eb16517785, createdName=ms1000000657368188, createdTime=Sat Dec 09 21:09:03 CST 2023, time=2023-12-09, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2187816, encodeId=a73f218e81621, content=审稿速度:6.0 | 投稿命中率:50.0<br>经验分享：9.28 投稿<br>9.30 修改格式 正式 under review<br>12.27 返回外审意见、<br>1.26 返修<br>1.27 编辑提出问题回答<br>2.15 再次返修<br>2.16接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=883e8850373, createdName=ms9000000079865054, createdTime=Sat Feb 17 21:01:29 CST 2024, time=2024-02-17, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2129832, encodeId=1a562129832f2, content=偏重的研究方向：肿瘤<br>经验分享：开帖求投稿经验 2023-2-14投稿综述 2023-2-17修改格式后，正式投稿并under review 2023-4-7发邮件问结果，立马有邮件返回说正在外审，还没有结果 2023-4-20再次发邮件问结果，立马有邮件返回说正在外审，仍旧没有结果 2023-5-3仍旧显示under review, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=126, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1917110347, createdName=ruiruima, createdTime=Wed May 03 12:28:26 CST 2023, time=2023-05-03, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1192333, encodeId=82e7119233345, content=审稿速度:1.0 | 投稿命中率:95.0<br>经验分享：12月10投，13外审，28出外审结果，2月5日修回，10接受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=172, replyNumber=18, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c4f5685200, createdName=ms9000001565211375, createdTime=Fri Feb 11 14:48:33 CST 2022, time=2022-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=580056, encodeId=46865800565a, content=文章接收了，下次不会再有这个杂志了，已被我们课题组拉入黑名单。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=161, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/c887015508b0c6ba53504e915b77a54c/59b1727e79c41e7236679601545c8119.jpg, createdBy=da932211214, createdName=牛肉盖饭菌, createdTime=Mon Nov 18 00:00:00 CST 2019, time=2019-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2171541, encodeId=96d121e15410e, content=求经验，想问问各位大佬，Under review编辑内审一般持续多长时间，进入peer review杂志社会发邮件吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=89, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16275416139, createdName=ms9000000361361306, createdTime=Tue Nov 28 20:44:38 CST 2023, time=2023-11-28, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2117052, encodeId=9b20211e052a1, content=偏重的研究方向：肿瘤;miRNA;卵巢癌<br>经验分享：2.14投稿<br>2.21改格式，Under review直到现在, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=117, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ffcd5307805, createdName=1487e742m42(暂无昵称), createdTime=Wed Mar 01 14:52:29 CST 2023, time=2023-03-01, status=1, ipAttribution=内蒙古), GetPortalCommentsPageByObjectIdResponse(id=2167435, encodeId=7e2f216e43593, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：癌症<br>经验分享：耗时五个月，五次返修，接受，编辑很好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230724/f6ff49274b4c450bb5ce22714896fd31/ef43ceb74c4f403797e71c4c086060e6.jpg, createdBy=33518647109, createdName=病理, createdTime=Wed Nov 08 17:28:30 CST 2023, time=2023-11-08, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2147312, encodeId=7b51214e31242, content=审稿速度:6.0 | 投稿命中率:95.0<br>偏重的研究方向：肿瘤;miRNA<br>经验分享：他的under review就是送外审，很久，我的从2月到6月等了四个月，然后6月返修7月就接收了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=114, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e85e8128411, createdName=ms1000000775790410, createdTime=Mon Jul 10 17:00:54 CST 2023, time=2023-07-10, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2114730, encodeId=9c2f2114e3000, content=开个贴分享投稿进度，求锦鲤...<br>2-5投稿，2-9要求改figure清晰度，当天返修，至今还是submitted, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=102, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8be8102949, createdName=ms7000002043514455, createdTime=Wed Feb 15 13:49:28 CST 2023, time=2023-02-15, status=1, ipAttribution=北京)]
    2024-02-17 ms9000000079865054 来自陕西省

    审稿速度:6.0 | 投稿命中率:50.0
    经验分享：9.28 投稿
    9.30 修改格式 正式 under review
    12.27 返回外审意见、
    1.26 返修
    1.27 编辑提出问题回答
    2.15 再次返修
    2.16接收

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2173925, encodeId=eff121e392549, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向：肿瘤<br>经验分享：2023.12.09投稿，开贴求经验, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8eb16517785, createdName=ms1000000657368188, createdTime=Sat Dec 09 21:09:03 CST 2023, time=2023-12-09, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2187816, encodeId=a73f218e81621, content=审稿速度:6.0 | 投稿命中率:50.0<br>经验分享：9.28 投稿<br>9.30 修改格式 正式 under review<br>12.27 返回外审意见、<br>1.26 返修<br>1.27 编辑提出问题回答<br>2.15 再次返修<br>2.16接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=883e8850373, createdName=ms9000000079865054, createdTime=Sat Feb 17 21:01:29 CST 2024, time=2024-02-17, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2129832, encodeId=1a562129832f2, content=偏重的研究方向：肿瘤<br>经验分享：开帖求投稿经验 2023-2-14投稿综述 2023-2-17修改格式后，正式投稿并under review 2023-4-7发邮件问结果，立马有邮件返回说正在外审，还没有结果 2023-4-20再次发邮件问结果，立马有邮件返回说正在外审，仍旧没有结果 2023-5-3仍旧显示under review, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=126, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1917110347, createdName=ruiruima, createdTime=Wed May 03 12:28:26 CST 2023, time=2023-05-03, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1192333, encodeId=82e7119233345, content=审稿速度:1.0 | 投稿命中率:95.0<br>经验分享：12月10投，13外审，28出外审结果，2月5日修回，10接受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=172, replyNumber=18, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c4f5685200, createdName=ms9000001565211375, createdTime=Fri Feb 11 14:48:33 CST 2022, time=2022-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=580056, encodeId=46865800565a, content=文章接收了，下次不会再有这个杂志了，已被我们课题组拉入黑名单。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=161, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/c887015508b0c6ba53504e915b77a54c/59b1727e79c41e7236679601545c8119.jpg, createdBy=da932211214, createdName=牛肉盖饭菌, createdTime=Mon Nov 18 00:00:00 CST 2019, time=2019-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2171541, encodeId=96d121e15410e, content=求经验，想问问各位大佬，Under review编辑内审一般持续多长时间，进入peer review杂志社会发邮件吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=89, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16275416139, createdName=ms9000000361361306, createdTime=Tue Nov 28 20:44:38 CST 2023, time=2023-11-28, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2117052, encodeId=9b20211e052a1, content=偏重的研究方向：肿瘤;miRNA;卵巢癌<br>经验分享：2.14投稿<br>2.21改格式，Under review直到现在, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=117, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ffcd5307805, createdName=1487e742m42(暂无昵称), createdTime=Wed Mar 01 14:52:29 CST 2023, time=2023-03-01, status=1, ipAttribution=内蒙古), GetPortalCommentsPageByObjectIdResponse(id=2167435, encodeId=7e2f216e43593, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：癌症<br>经验分享：耗时五个月，五次返修，接受，编辑很好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230724/f6ff49274b4c450bb5ce22714896fd31/ef43ceb74c4f403797e71c4c086060e6.jpg, createdBy=33518647109, createdName=病理, createdTime=Wed Nov 08 17:28:30 CST 2023, time=2023-11-08, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2147312, encodeId=7b51214e31242, content=审稿速度:6.0 | 投稿命中率:95.0<br>偏重的研究方向：肿瘤;miRNA<br>经验分享：他的under review就是送外审，很久，我的从2月到6月等了四个月，然后6月返修7月就接收了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=114, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e85e8128411, createdName=ms1000000775790410, createdTime=Mon Jul 10 17:00:54 CST 2023, time=2023-07-10, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2114730, encodeId=9c2f2114e3000, content=开个贴分享投稿进度，求锦鲤...<br>2-5投稿，2-9要求改figure清晰度，当天返修，至今还是submitted, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=102, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8be8102949, createdName=ms7000002043514455, createdTime=Wed Feb 15 13:49:28 CST 2023, time=2023-02-15, status=1, ipAttribution=北京)]
    2023-05-03 ruiruima 来自广东省

    偏重的研究方向：肿瘤
    经验分享：开帖求投稿经验 2023-2-14投稿综述 2023-2-17修改格式后，正式投稿并under review 2023-4-7发邮件问结果，立马有邮件返回说正在外审，还没有结果 2023-4-20再次发邮件问结果，立马有邮件返回说正在外审，仍旧没有结果 2023-5-3仍旧显示under review

    10

    展开10条回复
  4. [GetPortalCommentsPageByObjectIdResponse(id=2173925, encodeId=eff121e392549, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向：肿瘤<br>经验分享：2023.12.09投稿，开贴求经验, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8eb16517785, createdName=ms1000000657368188, createdTime=Sat Dec 09 21:09:03 CST 2023, time=2023-12-09, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2187816, encodeId=a73f218e81621, content=审稿速度:6.0 | 投稿命中率:50.0<br>经验分享：9.28 投稿<br>9.30 修改格式 正式 under review<br>12.27 返回外审意见、<br>1.26 返修<br>1.27 编辑提出问题回答<br>2.15 再次返修<br>2.16接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=883e8850373, createdName=ms9000000079865054, createdTime=Sat Feb 17 21:01:29 CST 2024, time=2024-02-17, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2129832, encodeId=1a562129832f2, content=偏重的研究方向：肿瘤<br>经验分享：开帖求投稿经验 2023-2-14投稿综述 2023-2-17修改格式后，正式投稿并under review 2023-4-7发邮件问结果，立马有邮件返回说正在外审，还没有结果 2023-4-20再次发邮件问结果，立马有邮件返回说正在外审，仍旧没有结果 2023-5-3仍旧显示under review, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=126, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1917110347, createdName=ruiruima, createdTime=Wed May 03 12:28:26 CST 2023, time=2023-05-03, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1192333, encodeId=82e7119233345, content=审稿速度:1.0 | 投稿命中率:95.0<br>经验分享：12月10投，13外审，28出外审结果，2月5日修回，10接受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=172, replyNumber=18, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c4f5685200, createdName=ms9000001565211375, createdTime=Fri Feb 11 14:48:33 CST 2022, time=2022-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=580056, encodeId=46865800565a, content=文章接收了，下次不会再有这个杂志了，已被我们课题组拉入黑名单。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=161, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/c887015508b0c6ba53504e915b77a54c/59b1727e79c41e7236679601545c8119.jpg, createdBy=da932211214, createdName=牛肉盖饭菌, createdTime=Mon Nov 18 00:00:00 CST 2019, time=2019-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2171541, encodeId=96d121e15410e, content=求经验，想问问各位大佬，Under review编辑内审一般持续多长时间，进入peer review杂志社会发邮件吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=89, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16275416139, createdName=ms9000000361361306, createdTime=Tue Nov 28 20:44:38 CST 2023, time=2023-11-28, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2117052, encodeId=9b20211e052a1, content=偏重的研究方向：肿瘤;miRNA;卵巢癌<br>经验分享：2.14投稿<br>2.21改格式，Under review直到现在, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=117, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ffcd5307805, createdName=1487e742m42(暂无昵称), createdTime=Wed Mar 01 14:52:29 CST 2023, time=2023-03-01, status=1, ipAttribution=内蒙古), GetPortalCommentsPageByObjectIdResponse(id=2167435, encodeId=7e2f216e43593, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：癌症<br>经验分享：耗时五个月，五次返修，接受，编辑很好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230724/f6ff49274b4c450bb5ce22714896fd31/ef43ceb74c4f403797e71c4c086060e6.jpg, createdBy=33518647109, createdName=病理, createdTime=Wed Nov 08 17:28:30 CST 2023, time=2023-11-08, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2147312, encodeId=7b51214e31242, content=审稿速度:6.0 | 投稿命中率:95.0<br>偏重的研究方向：肿瘤;miRNA<br>经验分享：他的under review就是送外审，很久，我的从2月到6月等了四个月，然后6月返修7月就接收了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=114, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e85e8128411, createdName=ms1000000775790410, createdTime=Mon Jul 10 17:00:54 CST 2023, time=2023-07-10, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2114730, encodeId=9c2f2114e3000, content=开个贴分享投稿进度，求锦鲤...<br>2-5投稿，2-9要求改figure清晰度，当天返修，至今还是submitted, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=102, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8be8102949, createdName=ms7000002043514455, createdTime=Wed Feb 15 13:49:28 CST 2023, time=2023-02-15, status=1, ipAttribution=北京)]
    2022-02-11 ms9000001565211375

    审稿速度:1.0 | 投稿命中率:95.0
    经验分享：12月10投，13外审，28出外审结果，2月5日修回，10接受

    18

    展开18条回复
  5. [GetPortalCommentsPageByObjectIdResponse(id=2173925, encodeId=eff121e392549, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向：肿瘤<br>经验分享：2023.12.09投稿，开贴求经验, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8eb16517785, createdName=ms1000000657368188, createdTime=Sat Dec 09 21:09:03 CST 2023, time=2023-12-09, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2187816, encodeId=a73f218e81621, content=审稿速度:6.0 | 投稿命中率:50.0<br>经验分享：9.28 投稿<br>9.30 修改格式 正式 under review<br>12.27 返回外审意见、<br>1.26 返修<br>1.27 编辑提出问题回答<br>2.15 再次返修<br>2.16接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=883e8850373, createdName=ms9000000079865054, createdTime=Sat Feb 17 21:01:29 CST 2024, time=2024-02-17, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2129832, encodeId=1a562129832f2, content=偏重的研究方向：肿瘤<br>经验分享：开帖求投稿经验 2023-2-14投稿综述 2023-2-17修改格式后，正式投稿并under review 2023-4-7发邮件问结果，立马有邮件返回说正在外审，还没有结果 2023-4-20再次发邮件问结果，立马有邮件返回说正在外审，仍旧没有结果 2023-5-3仍旧显示under review, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=126, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1917110347, createdName=ruiruima, createdTime=Wed May 03 12:28:26 CST 2023, time=2023-05-03, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1192333, encodeId=82e7119233345, content=审稿速度:1.0 | 投稿命中率:95.0<br>经验分享：12月10投，13外审，28出外审结果，2月5日修回，10接受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=172, replyNumber=18, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c4f5685200, createdName=ms9000001565211375, createdTime=Fri Feb 11 14:48:33 CST 2022, time=2022-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=580056, encodeId=46865800565a, content=文章接收了，下次不会再有这个杂志了，已被我们课题组拉入黑名单。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=161, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/c887015508b0c6ba53504e915b77a54c/59b1727e79c41e7236679601545c8119.jpg, createdBy=da932211214, createdName=牛肉盖饭菌, createdTime=Mon Nov 18 00:00:00 CST 2019, time=2019-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2171541, encodeId=96d121e15410e, content=求经验，想问问各位大佬，Under review编辑内审一般持续多长时间，进入peer review杂志社会发邮件吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=89, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16275416139, createdName=ms9000000361361306, createdTime=Tue Nov 28 20:44:38 CST 2023, time=2023-11-28, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2117052, encodeId=9b20211e052a1, content=偏重的研究方向：肿瘤;miRNA;卵巢癌<br>经验分享：2.14投稿<br>2.21改格式，Under review直到现在, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=117, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ffcd5307805, createdName=1487e742m42(暂无昵称), createdTime=Wed Mar 01 14:52:29 CST 2023, time=2023-03-01, status=1, ipAttribution=内蒙古), GetPortalCommentsPageByObjectIdResponse(id=2167435, encodeId=7e2f216e43593, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：癌症<br>经验分享：耗时五个月，五次返修，接受，编辑很好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230724/f6ff49274b4c450bb5ce22714896fd31/ef43ceb74c4f403797e71c4c086060e6.jpg, createdBy=33518647109, createdName=病理, createdTime=Wed Nov 08 17:28:30 CST 2023, time=2023-11-08, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2147312, encodeId=7b51214e31242, content=审稿速度:6.0 | 投稿命中率:95.0<br>偏重的研究方向：肿瘤;miRNA<br>经验分享：他的under review就是送外审，很久，我的从2月到6月等了四个月，然后6月返修7月就接收了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=114, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e85e8128411, createdName=ms1000000775790410, createdTime=Mon Jul 10 17:00:54 CST 2023, time=2023-07-10, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2114730, encodeId=9c2f2114e3000, content=开个贴分享投稿进度，求锦鲤...<br>2-5投稿，2-9要求改figure清晰度，当天返修，至今还是submitted, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=102, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8be8102949, createdName=ms7000002043514455, createdTime=Wed Feb 15 13:49:28 CST 2023, time=2023-02-15, status=1, ipAttribution=北京)]
    2019-11-18 牛肉盖饭菌

    文章接收了，下次不会再有这个杂志了，已被我们课题组拉入黑名单。

    9

    展开9条回复
  6. [GetPortalCommentsPageByObjectIdResponse(id=2173925, encodeId=eff121e392549, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向：肿瘤<br>经验分享：2023.12.09投稿，开贴求经验, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8eb16517785, createdName=ms1000000657368188, createdTime=Sat Dec 09 21:09:03 CST 2023, time=2023-12-09, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2187816, encodeId=a73f218e81621, content=审稿速度:6.0 | 投稿命中率:50.0<br>经验分享：9.28 投稿<br>9.30 修改格式 正式 under review<br>12.27 返回外审意见、<br>1.26 返修<br>1.27 编辑提出问题回答<br>2.15 再次返修<br>2.16接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=883e8850373, createdName=ms9000000079865054, createdTime=Sat Feb 17 21:01:29 CST 2024, time=2024-02-17, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2129832, encodeId=1a562129832f2, content=偏重的研究方向：肿瘤<br>经验分享：开帖求投稿经验 2023-2-14投稿综述 2023-2-17修改格式后，正式投稿并under review 2023-4-7发邮件问结果，立马有邮件返回说正在外审，还没有结果 2023-4-20再次发邮件问结果，立马有邮件返回说正在外审，仍旧没有结果 2023-5-3仍旧显示under review, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=126, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1917110347, createdName=ruiruima, createdTime=Wed May 03 12:28:26 CST 2023, time=2023-05-03, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1192333, encodeId=82e7119233345, content=审稿速度:1.0 | 投稿命中率:95.0<br>经验分享：12月10投，13外审，28出外审结果，2月5日修回，10接受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=172, replyNumber=18, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c4f5685200, createdName=ms9000001565211375, createdTime=Fri Feb 11 14:48:33 CST 2022, time=2022-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=580056, encodeId=46865800565a, content=文章接收了，下次不会再有这个杂志了，已被我们课题组拉入黑名单。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=161, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/c887015508b0c6ba53504e915b77a54c/59b1727e79c41e7236679601545c8119.jpg, createdBy=da932211214, createdName=牛肉盖饭菌, createdTime=Mon Nov 18 00:00:00 CST 2019, time=2019-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2171541, encodeId=96d121e15410e, content=求经验，想问问各位大佬，Under review编辑内审一般持续多长时间，进入peer review杂志社会发邮件吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=89, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16275416139, createdName=ms9000000361361306, createdTime=Tue Nov 28 20:44:38 CST 2023, time=2023-11-28, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2117052, encodeId=9b20211e052a1, content=偏重的研究方向：肿瘤;miRNA;卵巢癌<br>经验分享：2.14投稿<br>2.21改格式，Under review直到现在, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=117, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ffcd5307805, createdName=1487e742m42(暂无昵称), createdTime=Wed Mar 01 14:52:29 CST 2023, time=2023-03-01, status=1, ipAttribution=内蒙古), GetPortalCommentsPageByObjectIdResponse(id=2167435, encodeId=7e2f216e43593, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：癌症<br>经验分享：耗时五个月，五次返修，接受，编辑很好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230724/f6ff49274b4c450bb5ce22714896fd31/ef43ceb74c4f403797e71c4c086060e6.jpg, createdBy=33518647109, createdName=病理, createdTime=Wed Nov 08 17:28:30 CST 2023, time=2023-11-08, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2147312, encodeId=7b51214e31242, content=审稿速度:6.0 | 投稿命中率:95.0<br>偏重的研究方向：肿瘤;miRNA<br>经验分享：他的under review就是送外审，很久，我的从2月到6月等了四个月，然后6月返修7月就接收了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=114, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e85e8128411, createdName=ms1000000775790410, createdTime=Mon Jul 10 17:00:54 CST 2023, time=2023-07-10, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2114730, encodeId=9c2f2114e3000, content=开个贴分享投稿进度，求锦鲤...<br>2-5投稿，2-9要求改figure清晰度，当天返修，至今还是submitted, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=102, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8be8102949, createdName=ms7000002043514455, createdTime=Wed Feb 15 13:49:28 CST 2023, time=2023-02-15, status=1, ipAttribution=北京)]
    2023-11-28 ms9000000361361306 来自重庆

    求经验，想问问各位大佬，Under review编辑内审一般持续多长时间，进入peer review杂志社会发邮件吗？

    6

    展开6条回复
  7. [GetPortalCommentsPageByObjectIdResponse(id=2173925, encodeId=eff121e392549, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向：肿瘤<br>经验分享：2023.12.09投稿，开贴求经验, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8eb16517785, createdName=ms1000000657368188, createdTime=Sat Dec 09 21:09:03 CST 2023, time=2023-12-09, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2187816, encodeId=a73f218e81621, content=审稿速度:6.0 | 投稿命中率:50.0<br>经验分享：9.28 投稿<br>9.30 修改格式 正式 under review<br>12.27 返回外审意见、<br>1.26 返修<br>1.27 编辑提出问题回答<br>2.15 再次返修<br>2.16接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=883e8850373, createdName=ms9000000079865054, createdTime=Sat Feb 17 21:01:29 CST 2024, time=2024-02-17, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2129832, encodeId=1a562129832f2, content=偏重的研究方向：肿瘤<br>经验分享：开帖求投稿经验 2023-2-14投稿综述 2023-2-17修改格式后，正式投稿并under review 2023-4-7发邮件问结果，立马有邮件返回说正在外审，还没有结果 2023-4-20再次发邮件问结果，立马有邮件返回说正在外审，仍旧没有结果 2023-5-3仍旧显示under review, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=126, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1917110347, createdName=ruiruima, createdTime=Wed May 03 12:28:26 CST 2023, time=2023-05-03, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1192333, encodeId=82e7119233345, content=审稿速度:1.0 | 投稿命中率:95.0<br>经验分享：12月10投，13外审，28出外审结果，2月5日修回，10接受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=172, replyNumber=18, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c4f5685200, createdName=ms9000001565211375, createdTime=Fri Feb 11 14:48:33 CST 2022, time=2022-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=580056, encodeId=46865800565a, content=文章接收了，下次不会再有这个杂志了，已被我们课题组拉入黑名单。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=161, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/c887015508b0c6ba53504e915b77a54c/59b1727e79c41e7236679601545c8119.jpg, createdBy=da932211214, createdName=牛肉盖饭菌, createdTime=Mon Nov 18 00:00:00 CST 2019, time=2019-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2171541, encodeId=96d121e15410e, content=求经验，想问问各位大佬，Under review编辑内审一般持续多长时间，进入peer review杂志社会发邮件吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=89, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16275416139, createdName=ms9000000361361306, createdTime=Tue Nov 28 20:44:38 CST 2023, time=2023-11-28, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2117052, encodeId=9b20211e052a1, content=偏重的研究方向：肿瘤;miRNA;卵巢癌<br>经验分享：2.14投稿<br>2.21改格式，Under review直到现在, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=117, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ffcd5307805, createdName=1487e742m42(暂无昵称), createdTime=Wed Mar 01 14:52:29 CST 2023, time=2023-03-01, status=1, ipAttribution=内蒙古), GetPortalCommentsPageByObjectIdResponse(id=2167435, encodeId=7e2f216e43593, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：癌症<br>经验分享：耗时五个月，五次返修，接受，编辑很好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230724/f6ff49274b4c450bb5ce22714896fd31/ef43ceb74c4f403797e71c4c086060e6.jpg, createdBy=33518647109, createdName=病理, createdTime=Wed Nov 08 17:28:30 CST 2023, time=2023-11-08, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2147312, encodeId=7b51214e31242, content=审稿速度:6.0 | 投稿命中率:95.0<br>偏重的研究方向：肿瘤;miRNA<br>经验分享：他的under review就是送外审，很久，我的从2月到6月等了四个月，然后6月返修7月就接收了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=114, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e85e8128411, createdName=ms1000000775790410, createdTime=Mon Jul 10 17:00:54 CST 2023, time=2023-07-10, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2114730, encodeId=9c2f2114e3000, content=开个贴分享投稿进度，求锦鲤...<br>2-5投稿，2-9要求改figure清晰度，当天返修，至今还是submitted, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=102, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8be8102949, createdName=ms7000002043514455, createdTime=Wed Feb 15 13:49:28 CST 2023, time=2023-02-15, status=1, ipAttribution=北京)]
    2023-03-01 1487e742m42(暂无昵称) 来自内蒙古

    偏重的研究方向：肿瘤;miRNA;卵巢癌
    经验分享：2.14投稿
    2.21改格式，Under review直到现在

    6

    展开6条回复
  8. [GetPortalCommentsPageByObjectIdResponse(id=2173925, encodeId=eff121e392549, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向：肿瘤<br>经验分享：2023.12.09投稿，开贴求经验, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8eb16517785, createdName=ms1000000657368188, createdTime=Sat Dec 09 21:09:03 CST 2023, time=2023-12-09, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2187816, encodeId=a73f218e81621, content=审稿速度:6.0 | 投稿命中率:50.0<br>经验分享：9.28 投稿<br>9.30 修改格式 正式 under review<br>12.27 返回外审意见、<br>1.26 返修<br>1.27 编辑提出问题回答<br>2.15 再次返修<br>2.16接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=883e8850373, createdName=ms9000000079865054, createdTime=Sat Feb 17 21:01:29 CST 2024, time=2024-02-17, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2129832, encodeId=1a562129832f2, content=偏重的研究方向：肿瘤<br>经验分享：开帖求投稿经验 2023-2-14投稿综述 2023-2-17修改格式后，正式投稿并under review 2023-4-7发邮件问结果，立马有邮件返回说正在外审，还没有结果 2023-4-20再次发邮件问结果，立马有邮件返回说正在外审，仍旧没有结果 2023-5-3仍旧显示under review, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=126, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1917110347, createdName=ruiruima, createdTime=Wed May 03 12:28:26 CST 2023, time=2023-05-03, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1192333, encodeId=82e7119233345, content=审稿速度:1.0 | 投稿命中率:95.0<br>经验分享：12月10投，13外审，28出外审结果，2月5日修回，10接受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=172, replyNumber=18, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c4f5685200, createdName=ms9000001565211375, createdTime=Fri Feb 11 14:48:33 CST 2022, time=2022-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=580056, encodeId=46865800565a, content=文章接收了，下次不会再有这个杂志了，已被我们课题组拉入黑名单。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=161, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/c887015508b0c6ba53504e915b77a54c/59b1727e79c41e7236679601545c8119.jpg, createdBy=da932211214, createdName=牛肉盖饭菌, createdTime=Mon Nov 18 00:00:00 CST 2019, time=2019-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2171541, encodeId=96d121e15410e, content=求经验，想问问各位大佬，Under review编辑内审一般持续多长时间，进入peer review杂志社会发邮件吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=89, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16275416139, createdName=ms9000000361361306, createdTime=Tue Nov 28 20:44:38 CST 2023, time=2023-11-28, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2117052, encodeId=9b20211e052a1, content=偏重的研究方向：肿瘤;miRNA;卵巢癌<br>经验分享：2.14投稿<br>2.21改格式，Under review直到现在, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=117, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ffcd5307805, createdName=1487e742m42(暂无昵称), createdTime=Wed Mar 01 14:52:29 CST 2023, time=2023-03-01, status=1, ipAttribution=内蒙古), GetPortalCommentsPageByObjectIdResponse(id=2167435, encodeId=7e2f216e43593, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：癌症<br>经验分享：耗时五个月，五次返修，接受，编辑很好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230724/f6ff49274b4c450bb5ce22714896fd31/ef43ceb74c4f403797e71c4c086060e6.jpg, createdBy=33518647109, createdName=病理, createdTime=Wed Nov 08 17:28:30 CST 2023, time=2023-11-08, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2147312, encodeId=7b51214e31242, content=审稿速度:6.0 | 投稿命中率:95.0<br>偏重的研究方向：肿瘤;miRNA<br>经验分享：他的under review就是送外审，很久，我的从2月到6月等了四个月，然后6月返修7月就接收了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=114, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e85e8128411, createdName=ms1000000775790410, createdTime=Mon Jul 10 17:00:54 CST 2023, time=2023-07-10, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2114730, encodeId=9c2f2114e3000, content=开个贴分享投稿进度，求锦鲤...<br>2-5投稿，2-9要求改figure清晰度，当天返修，至今还是submitted, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=102, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8be8102949, createdName=ms7000002043514455, createdTime=Wed Feb 15 13:49:28 CST 2023, time=2023-02-15, status=1, ipAttribution=北京)]
    2023-11-08 病理 来自安徽省

    审稿速度:1.0 | 投稿命中率:50.0
    偏重的研究方向：癌症
    经验分享：耗时五个月，五次返修，接受，编辑很好

    5

    展开5条回复
  9. [GetPortalCommentsPageByObjectIdResponse(id=2173925, encodeId=eff121e392549, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向：肿瘤<br>经验分享：2023.12.09投稿，开贴求经验, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8eb16517785, createdName=ms1000000657368188, createdTime=Sat Dec 09 21:09:03 CST 2023, time=2023-12-09, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2187816, encodeId=a73f218e81621, content=审稿速度:6.0 | 投稿命中率:50.0<br>经验分享：9.28 投稿<br>9.30 修改格式 正式 under review<br>12.27 返回外审意见、<br>1.26 返修<br>1.27 编辑提出问题回答<br>2.15 再次返修<br>2.16接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=883e8850373, createdName=ms9000000079865054, createdTime=Sat Feb 17 21:01:29 CST 2024, time=2024-02-17, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2129832, encodeId=1a562129832f2, content=偏重的研究方向：肿瘤<br>经验分享：开帖求投稿经验 2023-2-14投稿综述 2023-2-17修改格式后，正式投稿并under review 2023-4-7发邮件问结果，立马有邮件返回说正在外审，还没有结果 2023-4-20再次发邮件问结果，立马有邮件返回说正在外审，仍旧没有结果 2023-5-3仍旧显示under review, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=126, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1917110347, createdName=ruiruima, createdTime=Wed May 03 12:28:26 CST 2023, time=2023-05-03, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1192333, encodeId=82e7119233345, content=审稿速度:1.0 | 投稿命中率:95.0<br>经验分享：12月10投，13外审，28出外审结果，2月5日修回，10接受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=172, replyNumber=18, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c4f5685200, createdName=ms9000001565211375, createdTime=Fri Feb 11 14:48:33 CST 2022, time=2022-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=580056, encodeId=46865800565a, content=文章接收了，下次不会再有这个杂志了，已被我们课题组拉入黑名单。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=161, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/c887015508b0c6ba53504e915b77a54c/59b1727e79c41e7236679601545c8119.jpg, createdBy=da932211214, createdName=牛肉盖饭菌, createdTime=Mon Nov 18 00:00:00 CST 2019, time=2019-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2171541, encodeId=96d121e15410e, content=求经验，想问问各位大佬，Under review编辑内审一般持续多长时间，进入peer review杂志社会发邮件吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=89, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16275416139, createdName=ms9000000361361306, createdTime=Tue Nov 28 20:44:38 CST 2023, time=2023-11-28, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2117052, encodeId=9b20211e052a1, content=偏重的研究方向：肿瘤;miRNA;卵巢癌<br>经验分享：2.14投稿<br>2.21改格式，Under review直到现在, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=117, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ffcd5307805, createdName=1487e742m42(暂无昵称), createdTime=Wed Mar 01 14:52:29 CST 2023, time=2023-03-01, status=1, ipAttribution=内蒙古), GetPortalCommentsPageByObjectIdResponse(id=2167435, encodeId=7e2f216e43593, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：癌症<br>经验分享：耗时五个月，五次返修，接受，编辑很好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230724/f6ff49274b4c450bb5ce22714896fd31/ef43ceb74c4f403797e71c4c086060e6.jpg, createdBy=33518647109, createdName=病理, createdTime=Wed Nov 08 17:28:30 CST 2023, time=2023-11-08, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2147312, encodeId=7b51214e31242, content=审稿速度:6.0 | 投稿命中率:95.0<br>偏重的研究方向：肿瘤;miRNA<br>经验分享：他的under review就是送外审，很久，我的从2月到6月等了四个月，然后6月返修7月就接收了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=114, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e85e8128411, createdName=ms1000000775790410, createdTime=Mon Jul 10 17:00:54 CST 2023, time=2023-07-10, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2114730, encodeId=9c2f2114e3000, content=开个贴分享投稿进度，求锦鲤...<br>2-5投稿，2-9要求改figure清晰度，当天返修，至今还是submitted, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=102, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8be8102949, createdName=ms7000002043514455, createdTime=Wed Feb 15 13:49:28 CST 2023, time=2023-02-15, status=1, ipAttribution=北京)]
    2023-07-10 ms1000000775790410 来自四川省

    审稿速度:6.0 | 投稿命中率:95.0
    偏重的研究方向：肿瘤;miRNA
    经验分享：他的under review就是送外审，很久，我的从2月到6月等了四个月，然后6月返修7月就接收了

    3

    展开3条回复
  10. [GetPortalCommentsPageByObjectIdResponse(id=2173925, encodeId=eff121e392549, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向：肿瘤<br>经验分享：2023.12.09投稿，开贴求经验, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8eb16517785, createdName=ms1000000657368188, createdTime=Sat Dec 09 21:09:03 CST 2023, time=2023-12-09, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2187816, encodeId=a73f218e81621, content=审稿速度:6.0 | 投稿命中率:50.0<br>经验分享：9.28 投稿<br>9.30 修改格式 正式 under review<br>12.27 返回外审意见、<br>1.26 返修<br>1.27 编辑提出问题回答<br>2.15 再次返修<br>2.16接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=883e8850373, createdName=ms9000000079865054, createdTime=Sat Feb 17 21:01:29 CST 2024, time=2024-02-17, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2129832, encodeId=1a562129832f2, content=偏重的研究方向：肿瘤<br>经验分享：开帖求投稿经验 2023-2-14投稿综述 2023-2-17修改格式后，正式投稿并under review 2023-4-7发邮件问结果，立马有邮件返回说正在外审，还没有结果 2023-4-20再次发邮件问结果，立马有邮件返回说正在外审，仍旧没有结果 2023-5-3仍旧显示under review, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=126, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1917110347, createdName=ruiruima, createdTime=Wed May 03 12:28:26 CST 2023, time=2023-05-03, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1192333, encodeId=82e7119233345, content=审稿速度:1.0 | 投稿命中率:95.0<br>经验分享：12月10投，13外审，28出外审结果，2月5日修回，10接受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=172, replyNumber=18, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c4f5685200, createdName=ms9000001565211375, createdTime=Fri Feb 11 14:48:33 CST 2022, time=2022-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=580056, encodeId=46865800565a, content=文章接收了，下次不会再有这个杂志了，已被我们课题组拉入黑名单。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=161, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/c887015508b0c6ba53504e915b77a54c/59b1727e79c41e7236679601545c8119.jpg, createdBy=da932211214, createdName=牛肉盖饭菌, createdTime=Mon Nov 18 00:00:00 CST 2019, time=2019-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2171541, encodeId=96d121e15410e, content=求经验，想问问各位大佬，Under review编辑内审一般持续多长时间，进入peer review杂志社会发邮件吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=89, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16275416139, createdName=ms9000000361361306, createdTime=Tue Nov 28 20:44:38 CST 2023, time=2023-11-28, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2117052, encodeId=9b20211e052a1, content=偏重的研究方向：肿瘤;miRNA;卵巢癌<br>经验分享：2.14投稿<br>2.21改格式，Under review直到现在, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=117, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ffcd5307805, createdName=1487e742m42(暂无昵称), createdTime=Wed Mar 01 14:52:29 CST 2023, time=2023-03-01, status=1, ipAttribution=内蒙古), GetPortalCommentsPageByObjectIdResponse(id=2167435, encodeId=7e2f216e43593, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：癌症<br>经验分享：耗时五个月，五次返修，接受，编辑很好, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230724/f6ff49274b4c450bb5ce22714896fd31/ef43ceb74c4f403797e71c4c086060e6.jpg, createdBy=33518647109, createdName=病理, createdTime=Wed Nov 08 17:28:30 CST 2023, time=2023-11-08, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2147312, encodeId=7b51214e31242, content=审稿速度:6.0 | 投稿命中率:95.0<br>偏重的研究方向：肿瘤;miRNA<br>经验分享：他的under review就是送外审，很久，我的从2月到6月等了四个月，然后6月返修7月就接收了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=114, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e85e8128411, createdName=ms1000000775790410, createdTime=Mon Jul 10 17:00:54 CST 2023, time=2023-07-10, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2114730, encodeId=9c2f2114e3000, content=开个贴分享投稿进度，求锦鲤...<br>2-5投稿，2-9要求改figure清晰度，当天返修，至今还是submitted, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=102, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8be8102949, createdName=ms7000002043514455, createdTime=Wed Feb 15 13:49:28 CST 2023, time=2023-02-15, status=1, ipAttribution=北京)]
    2023-02-15 ms7000002043514455 来自北京

    开个贴分享投稿进度，求锦鲤...
    2-5投稿，2-9要求改figure清晰度，当天返修，至今还是submitted

    12

    展开12条回复
共500条页码: 1/50页10条/页
分享您的投稿经验，提升MI经验值，获取更多积分

Baidu
Baidu
map
Baidu
map
Baidu
map